The tumor microenvironment is a dominant force in multidrug resistance

被引：451

作者：

Correia, Ana Luisa ^{[1
,2
]}

Bissell, Mina J. ^{[1
]}

机构：

[1] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA

[2] Univ Porto, GABBA, Abel Salazar Inst Biomed Sci ICBAS, P-4099003 Oporto, Portugal

来源：

DRUG RESISTANCE UPDATES | 2012年 / 15卷 / 1-2期

关键词：

Microenvironment; Context; Tumor-stroma interactions; Dormancy; Multidrug resistance; BREAST-CANCER CELLS; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; RECONSTITUTED BASEMENT-MEMBRANE; EXTRACELLULAR-MATRIX PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; TO-MESENCHYMAL TRANSITION; MINIMAL RESIDUAL DISEASE; ALUI RESTRICTION ENZYME; ROUS-SARCOMA VIRUS;

D O I：

10.1016/j.drup.2012.01.006

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

The emergence of clinical drug resistance is still one of the most challenging factors in cancer treatment effectiveness. Until more recently, the assumption has been that random genetic lesions are sufficient to explain the progression of malignancy and escape from chemotherapy. Here we propose an additional perspective, one in which the tumor cells despite the malignant genome could find a microenvironment either within the tumor or as a dormant cell to remain polar and blend into an organized context. Targeting this dynamic interplay could be considered a new avenue to prevent therapeutic resistance, and may even provide a promising effective cancer treatment. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.

引用

页码：39 / 49

页数：11

共 165 条

[1]

Disruption of 3D tissue integrity facilitates adenovirus infection by deregulating the coxsackievirus and adenovirus receptor [J].